← Back to Clinical Trials
Recruiting NCT05935709

NCT05935709 DANIsh VASculitis Database (DANIVAS)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05935709
Status Recruiting
Phase
Sponsor Aarhus University Hospital
Condition Giant Cell Arteritis
Study Type OBSERVATIONAL
Enrollment 3,000 participants
Start Date 2023-11-10
Primary Completion 2034-12-31

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 3,000 participants in total. It began in 2023-11-10 with a primary completion date of 2034-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this national pragmatic observational study is to investigate whether the use of new diagnostic imaging modalities facilitates disease stratification that can potentially predict treatment response, relapse risk and complications and hence guide management strategies to improve disease control and reduce disease and treatment related damage.

Eligibility Criteria

Inclusion Criteria: * Are diagnosed with GCA or PMR within the last 5 years * Diagnosis is established by or confirmed by a rheumatologist (clinical expert opinion) * Speak and understand Danish * Are able to give signed and dated informed consent Exclusion Criteria: * Denies or are not able to give informed consent * Are diagnosed with other systemic autoimmune diseases that out-rules the diagnosis of GCA or PMR

Contact & Investigator

Central Contact

Agnete Overgaard Donskov, MD

✉ agnead@rm.dk

📞 +4530225709

Principal Investigator

Berit Dalsgaard Nielsen, Ass prof

PRINCIPAL INVESTIGATOR

Led og Bindevæv, Aarhus University Hospital, Palle Juul-Jensens Boulevard 59, 8200 Aarhus N, DK

Frequently Asked Questions

Who can join the NCT05935709 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, studying Giant Cell Arteritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05935709 currently recruiting?

Yes, NCT05935709 is actively recruiting participants. Contact the research team at agnead@rm.dk for enrollment information.

Where is the NCT05935709 trial being conducted?

This trial is being conducted at Aarhus, Denmark, Horsens, Denmark.

Who is sponsoring the NCT05935709 clinical trial?

NCT05935709 is sponsored by Aarhus University Hospital. The principal investigator is Berit Dalsgaard Nielsen, Ass prof at Led og Bindevæv, Aarhus University Hospital, Palle Juul-Jensens Boulevard 59, 8200 Aarhus N, DK. The trial plans to enroll 3,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology